Similar to our results, studies have also reported that overexpression of SFN can be used as a better prognostic biomarker in gallbladder cancer [22] and the stroma of pancreatic ductal adenocarcinoma (PDAC) treatment [56]. The gene discussed is SFN; the disease is pancreatic ductal adenocarcinoma.